Infections ostéoarticulaires (IOA) en réanimation

[1]  H. Migaud,et al.  Épidémiologie bactérienne des infections ostéo-articulaires dans un centre de référence : étude sur 10 ans , 2013 .

[2]  P. Verde,et al.  Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Natanson,et al.  Excess deaths associated with tigecycline after approval based on noninferiority trials. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Bettencourt,et al.  Daptomycin: a review of properties, clinical use, drug delivery and resistance. , 2012, Mini reviews in medicinal chemistry.

[5]  R. López-Rojas,et al.  Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant Staphylococcus epidermidis , 2011, Antimicrobial Agents and Chemotherapy.

[6]  F. Guaraldi,et al.  Validity of preoperative ultrasound-guided aspiration in the revision of hip prosthesis. , 2011, Ultrasound in medicine & biology.

[7]  Thierry Naas,et al.  Global Spread of Carbapenemase-producing Enterobacteriaceae , 2011, Emerging infectious diseases.

[8]  L. Leibovici,et al.  Efficacy and safety of tigecycline: a systematic review and meta-analysis. , 2011, The Journal of antimicrobial chemotherapy.

[9]  W. Witte,et al.  Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge. , 2011, Future microbiology.

[10]  Henri Migaud,et al.  Outcome and Predictors of Treatment Failure in Total Hip/Knee Prosthetic Joint Infections Due to Staphylococcus aureus , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. Muller-Serieys,et al.  Adjunctive Rifampin Is Crucial to Optimizing Daptomycin Efficacy against Rabbit Prosthetic Joint Infection Due to Methicillin-Resistant Staphylococcus aureus , 2011, Antimicrobial Agents and Chemotherapy.

[12]  Rosário Oliveira,et al.  In vitro Activity of Daptomycin, Linezolid and Rifampicin on Staphylococcus epidermidis Biofilms , 2011, Current Microbiology.

[13]  M. Dryden.  Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. , 2011, The Journal of antimicrobial chemotherapy.

[14]  E. Urbán,et al.  Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  E. Urbán,et al.  ESCMID Study group on Antimicrobial resistance in anaerobic bacteria , 2011 .

[16]  I. Sia,et al.  Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[17]  Orgn. Spilf.  Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). Société de Pathologie Infectieuse de Langue Française. , 2010, Medecine et maladies infectieuses.

[18]  R. Porcher,et al.  Decreased Susceptibility to Teicoplanin and Vancomycin in Coagulase-Negative Staphylococci Isolated from Orthopedic-Device-Associated Infections , 2010, Journal of Clinical Microbiology.

[19]  M. Leunig,et al.  Improved Diagnosis of Periprosthetic Joint Infection by Multiplex PCR of Sonication Fluid from Removed Implants , 2010, Journal of Clinical Microbiology.

[20]  G. Drusano,et al.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  L. Leibovici,et al.  Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis , 2009, Antimicrobial Agents and Chemotherapy.

[22]  F. Doucet-Populaire,et al.  In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[23]  P. Bejon,et al.  One hundred and twelve infected arthroplasties treated with ‘DAIR’ (debridement, antibiotics and implant retention): antibiotic duration and outcome , 2009, The Journal of antimicrobial chemotherapy.

[24]  Å. Nilsdotter-Augustinsson,et al.  Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  S. Aslam.  Effect of antibacterials on biofilms. , 2008, American journal of infection control.

[26]  W. Zimmerli,et al.  Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis , 2008, Current infectious disease reports.

[27]  Elizabeth Weekes,et al.  Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused by Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[28]  Y. Yazdanpanah,et al.  Safety of Prolonged High-Dose Levofloxacin Therapy for Bone Infections , 2007, Journal of chemotherapy.

[29]  E. Moran,et al.  Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. , 2007, The Journal of infection.

[30]  Y. Yazdanpanah,et al.  Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[31]  Y. Yazdanpanah,et al.  Improved aero-anaerobe recovery from infected prosthetic joint samples taken from 72 patients and collected intraoperatively in Rosenow's broth , 2006, Acta orthopaedica.

[32]  J. Barberán.  Management of infections of osteoarticular prosthesis. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  W. Zimmerli,et al.  Prosthetic joint infections: update in diagnosis and treatment. , 2005, Swiss medical weekly.

[34]  F. Pea,et al.  Levofloxacin PK/PD: from Sequential Therapy Model to High Dosage for Critical Patients , 2004, Journal of chemotherapy.

[35]  C E Nord,et al.  Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[36]  P. Taourel,et al.  Painful infection at the site of hip prosthesis: CT imaging. , 2002, Radiology.

[37]  B. Allaouchiche,et al.  [Diffusion in bone tissue of antibiotics]. , 1999, Presse medicale.

[38]  H. Simmen,et al.  Bacterial concentrations in pus and infected peritoneal fluid--implications for bactericidal activity of antibiotics. , 1998, The Journal of antimicrobial chemotherapy.

[39]  P E Ochsner,et al.  Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. , 1998, JAMA.

[40]  P. François,et al.  Host-Bacteria Interactions in Foreign Body Infections , 1996, Infection Control & Hospital Epidemiology.

[41]  A. Widmer,et al.  Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.